Bridge Laboratories wins contract from NIDA
The single award contract has a five-year base period of performance for an estimated value of $4.1 million if all options are exercised. Under the new contract, Bridge
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).